The objective of this multicentre retrospective study was to describe clinical presentation, treatment and outcome and to determine prognostic factors for dogs with presumed primary colorectal lymphoma (PCRL). A total of 31 dogs were included. The predominant features of PCRL were high grade (n = 18) and immunophenotype B (n = 24). Most dogs were substage b (n = 25) with higher prevalence of haematochezia (n = 20). One dog had surgery only. Thirty dogs received chemotherapy; amongst them 13 had surgery or radiotherapy. Progression free survival (PFS) was 1318 days and disease-related median survival time (MST) was 1845 days. Fourteen dogs were alive at the end of the study with a median follow-up time of 684 days (3-4678 days). Younger dogs had longer PFS (P = 0.031) and disease-related MST (P = 0.01). Presence of haematochezia corresponded with longer PFS (P = 0.02). Addition of local treatment to chemotherapy did not significantly improve the outcome (P = 0.584). Canine PCRL has considerably longer PFS and MST than other forms of non-Hodgkin's lymphoma.
Introduction
Canine gastrointestinal (GI) lymphoma, also named alimentary lymphoma (AL), is second in frequency to the multicentric form and accounts for 5-7% of all canine lymphomas. 1 In human medicine, AL is defined according to Dawson's criteria 2 (Fig. 1) , in which the lymphoma is considered alimentary only if the predominant lesion lies within the GI tract, with lymph node involvement for canine AL ranges from 0.5 to 2.5 months 4, 5 versus from 10 to 12 months for the multicentric form. 1 This difference in prognosis can be attributed to the negative prognostic factors carried by the most common presentation of canine GI lymphoma: T-cell immunophenotype, high grade and substage b. 4 -7 However, dogs with AL typically do worse than dogs with multicentric lymphoma carrying similar negative prognostic factors, so it is unknown if there are additional inherent features of AL, such as specific morphologic subtype that could account for its poorer prognosis. Chemotherapy and supportive care are the standard treatments for AL in dogs. A specific chemotherapy protocol (VELCAP-SC: vincristine, L-asparaginase, cyclophosphamide, doxorubicin, prednisolone -short, consolidated) for canine AL resulted in an overall MST of 77 days for the whole population and of 117 days for the chemotherapy responders. 4 Primary large intestinal lymphoma can arise primarily from the colon, rectum or both. In human medicine, it is referred to as primary colorectal lymphoma (PCRL) regardless of the segment of large intestine it is originating from. Canine PCRL is a rare presentation of AL, which has been sparsely described in the veterinary literature within case series reporting information about response and outcome for all GI locations. 3 -6,8 When specific information for dogs with large intestinal lymphoma has been reported in those studies, a better outcome than other GI locations has been observed 3 -5,8,9 with remission times up to 54 months (Table 1) . A recent case series of 11 dogs with rectal lymphoma treated with surgery (7/11) and/or chemotherapy (8/11) described a mean survival time of 1697 days, with a median not reached. 10 This data suggest that PCRL could have a better prognosis than AL in other locations. Such difference in prognosis could have implications in veterinary practice as some owners or veterinarians might be reluctant to treat dogs diagnosed with PCRL because of the currently described overall poor prognosis for AL. Questions that remain unanswered at the moment are: if studies with a higher number of patients would corroborate a distinct prognosis and a specific clinical presentation for canine PCRL; which prognostic factors are associated with this presentation and which therapeutic approach would have the best outcome. The purpose of the present multicentre retrospective study is to provide further information to answer those questions.
Material and methods

Case selection
Dogs were presumed to have PCRL if they lack peripheral lymphadenopathy, a cytologic or histologic diagnosis of lymphoma had been made based on the examination of a mass or diffuse intestinal wall infiltration of rectum, colon or both, and the main clinical signs at presentation were associated with large intestinal involvement. Dogs with concurrent abdominal lymphadenopathy, hepatomegaly and splenomegaly were eligible for inclusion. Exclusion criteria included presence of gross disease in other areas of the GI tract evidenced by abdominal imaging or direct visualization at surgery.
The Histological re-evaluation was performed for all cases for which samples were available. Lymphoma grading was performed with grading system used at the discretion of the pathologist reviewing the slides for cases with histopathology and according to cell size for those with cytological diagnosis. 11 -13 Immunohistochemistry or immunocytochemistry was performed using antibodies against CD3 and CD79 for all cases for which samples were available and in which immunophenotyping had not been performed. Immunophenotyping was also performed with polymerase chain reaction (PCR) for antigen receptor re-arrangement (PARR) in some cases.
Dogs were clinically staged at diagnosis according to the World Health Organization (WHO) criteria for canine lymphoma. 1 Response to treatment was classified according to remission status recorded by the veterinarian providing the data using the following categories: complete response (CR), partial response (PR), stable disease and progressive disease. Response to treatment was mainly determined based on the results of clinical examination and assessment of progression of clinical signs. When available, follow-up abdominal ultrasound examinations were used to assess for changes in internal organs. CR was defined as resolution of all clinical signs and disappearance of all clinical evidence of disease on the basis of physical examination (via rectal and abdominal palpation) or follow-up abdominal ultrasound examination. PR was defined as (≥) 50 and (<) 100% reduction in size of measurable disease on the basis of physical examination (via rectal and abdominal palpation) or follow-up abdominal ultrasound examination associated or not with improvement of the clinical signs. No response was defined as no changes or deterioration in clinical signs, and less than 50% reduction, increase in the size of measurable disease or appearance of new lesions on the basis of physical examination (via rectal and abdominal palpation) or follow-up abdominal ultrasound examination. 14 When surgery was performed prior to chemotherapy, only dogs with residual macroscopic disease were included in the assessment of response to chemotherapy.
Statistical analysis
Categorical data are presented either as percentages or ratios. Continuous data are presented as median (range). Survival time was defined as the time from diagnosis until natural death or euthanasia. Deaths as a result of disease progression were considered events for the disease-related MST. Dogs that were lost to follow-up, still alive at the end of the study period or died from causes unrelated to the lymphoma were censored. In addition, overall survival time was also calculated. Because of the small number of patients that died from lymphoma, this variable included all deaths as events (related to lymphoma or unrelated) with dogs lost to follow-up or still alive at the end of the study period being censored. Progression free survival (PFS) was defined as the time from initiation of treatment to event. For this variable, the date of relapse was considered as the endpoint for dogs when this occurred. Dogs that had not relapsed during the study period were censored at the last date they were contacted or evaluated by the vet or the date of death free of disease.
After a statistical description of patient population, survival analysis using Kaplan-Meier product limit method was conducted to estimate disease-related MST, overall MST, and PFS, for the whole population of PCRL patients. Disease-related MST and PFS of dogs distributed in groups on the basis of various potential risk factors (univariate analysis) were also calculated. Exploratory statistical analysis for each categorical risk factors (age, location of the disease, involvement of organs other than the large intestine, substage, number of clinical signs present, type of clinical signs (local versus systemic), grade, immunophenotype, treatment type, chemotherapy protocol) used the log-rank test to compare estimated PFS and disease-related MST between categories. Multivariate analysis was not performed because of the small number of animals in each group and high censorship of dogs in the study. A value of P ≤ 0.05 was considered significant. All calculations were performed with the aid of standard statistical software (SPSS version 19.0 for Windows, SPSS Inc, Chicago, IL).
Results
Signalment
A total of 31 dogs met the inclusion criteria for this study and consisted of 17 spayed females and 14 males (12 neutered and 2 intact). The median age at diagnosis was 5 years (range: 1.5-13.5 years). Median weight was 23.8 kg (range: 5.9-52.1 kg). The most common breeds were cross breeds (seven dogs; 22.6%) and Labrador retrievers (four dogs; 12.9%).
Clinical signs at diagnosis
Presenting clinical signs were known for 29 of 31 dogs. Twenty-five (80.64%) dogs had clinical signs at presentation associated with the disease and were considered substage b. Haematochezia was the most common presenting clinical sign (n = 20; 64.5%) with 13 of these dogs presenting additional clinical signs. Other reported clinical signs included: tenesmus in 35.6 % (n = 11), diarrhoea in 25.8% (n = 8), narrow diameter of faeces in 12.9% (n = 4), vomiting in 3.4% (n = 1) and lethargy in 3.4% (n = 1). Eighteen dogs (58%) had simultaneously two to four different clinical signs and seven dogs (22.5%) had one clinical sign at presentation. Presence of a rectal mass was described on physical examination in 35.6 % (n = 11) and rectal prolapse in 9.68% (n = 3). The median duration of clinical signs was 21 days (range: 1-120 days) for the 28 dogs for which this information was available.
Staging and location of the disease
As per inclusion criteria, none of the dogs had peripheral lymphadenopathy identified on physical examination. Imaging was performed in 29 patients: 2 dogs had imaging of thorax and abdomen as well as bone marrow evaluation, 19 had imaging of the thorax and abdomen, 7 dogs had only abdominal imaging and 1 had only thoracic imaging. Abdominal imaging consisted of ultrasonography in 24 dogs, radiographs in 2 and computed tomography in 2. Thoracic imaging was performed in 2 dogs with CT scan and in 20 with radiographs. Dogs that did not have abdominal imaging had direct evaluation of the GI tract via laparotomy or endoscopy.
A solitary mass was found in 23 patients (17 rectal masses of which 4 dogs also had regional lymph node involvement, 6 colonic masses of which 5 dogs also had regional lymph node involvement). Multiple masses were identified in five patients, with one dog having multiple masses in the rectum, one dog with multiple masses in the colon and three dogs having masses occurring in both areas. Three dogs were determined to have lymphoma diffusely throughout the colorectal region. Regional lymphadenopathy was present in 12 dogs with lymphoma confirmed by lymph node cytology for 8 dogs. Splenic aspirates were performed in two dogs and liver aspirates in four dogs. Liver involvement was confirmed in one dog based on cytology.
Immunophenotype and grade
Three cases were diagnosed via cytology and 28 by histopathology. Histological or cytological assessment of lymphoma grade was reported for 29 cases (94%) and 2 cases were reported to be low grade lymphoma, 9 were intermediate grade lymphoma and 18 high-grade lymphoma ( Table 2) . Slides of 22 cases were obtained for review by a pathologist (7 different pathologists reviewed all the slides with 2 of them reviewing a total of 16 slides -KS and BP), in those confirmation of diagnosis and grade was performed. None of the cases which had a grade previously carried out and for which histopathology slides were reviewed had a change in their grade. Immunophenotype was available for 26 patients (84%). It was performed via immunohistochemistry for 23 dogs and this took place at the time of pathology review for 12 cases. Immunophenotype was determined by immunocytochemistry for two dogs and PARR for one dog. There were 24 B-cell lymphomas, 1 T-cell lymphoma and 1 non-B non-T-cell lymphoma (Table 2) .
Treatment and response to treatment
All dogs received therapy, and all but one (that had only surgery) received chemotherapy as part of the treatment plan. Seventeen patients (55.5%) received chemotherapy as a sole treatment and 13 (42%) received chemotherapy in addition to local treatment. Nine dogs (29%) had surgery prior to adjuvant chemotherapy. Four dogs (13%) had chemotherapy combined with radiation therapy. These cases received radiation therapy with photons; protocols comprised hypofractionated regimens for three dogs (two dogs received two fractions of 6 Gy and one dog received one fraction of 6 Gy), and the fourth dog was treated with a hyperfractionated protocol (19 fractions of 1.5 Gy). One dog (2.5%) had surgery alone.
Out of the 10 patients that had surgery, 9 dogs (29%) presented with a solitary mass. The remaining dog had a solitary mass removed from the rectum and was found to have diffuse disease in the colon at later staging. Two dogs also had lymph node involvement and one of them had the lymph nodes biopsied at the same surgery. Eight dogs (25.8%) had surgery performed by the referring vet prior to referral and there was no evidence of previous diagnosis based on cytology or biopsy for the two remaining dogs so it is likely that surgery in the 10 patients was performed as a mean to obtain a diagnosis as well as therapeutic procedure. Because of the retrospective nature of the study, the primary intent of performing surgery could not be ascertained. Type of surgery was recorded for two patients: one had mucosal resection and one had end-to-end anastomosis. The latter procedure was performed because the dog was initially referred for a rectal polyp previously diagnosed on endoscopic biopsies performed by the referring vet and lymphoma was diagnosed on the surgical histopathology. Eight patients out of the 28 diagnosed via histopathology (25.8%) had endoscopic biopsies.
The distribution of induction chemotherapy protocols used was as follows: 18 (58.1%) patients received a CHOP type protocol, 5 dogs (16%) had a COP type protocol, 3 (10%) had a lomustine-based protocol (lomustine/vincristine/ cyclophosphamide; lomustine/prednisolone or lomustine/prednisolone/L-asparaginase, respectively), 1 dog (2.5%) had doxorubicin single agent and prednisolone, 1 dog (2.5%) had chlorambucil and prednisolone and 2 dogs (5%) received only prednisolone. The response rate to chemotherapy for the 22 dogs that had gross disease at the start of chemotherapy (only one of the dogs that had surgery had gross residual disease at the start of chemotherapy) was available in the records of 19 dogs (86%). The overall response rate was 100% with 18 dogs (95%) having a CR and 1 dog (5%) having a PR.
The estimated PFS was 1318 days, because 71% of dogs were censored the confidence interval (CI) is not available. Nine patients had a relapse during the follow-up period and re-induction with a chemotherapy protocol was attempted in eight of them (six dogs received one additional protocol, one dog received two and one received five additional protocols). Chemotherapy protocols used for re-induction comprised: lomustine/prednisolone with or without L-asparaginase, CHOP, COP, vincristine/chlorambucil, doxorubicin single agent or vincristine single agent. Two dogs were euthanized the same day that the chemotherapy was resumed. Response was available for five out of the six remaining dogs and all had a CR. The median remission duration for these five dogs, after the first re-induction protocol was initiated, was 411 days (range: 298-938).
Outcome
At the end of the study period, 14 dogs were still alive, 5 dogs were lost to follow-up, 7 dogs died of lymphoma and 5 dogs died of unrelated causes (1 intramuscular hemangiosarcoma, 1 suspected osteosarcoma, 1 chronic kidney disease and 2 unknown cause). Only one dog underwent necropsy and disseminated lymphoma was found to be the cause of his death. The median follow-up time was 684 days (range: 3-4678 days). The estimated disease-related MST, where only dogs that died from lymphoma were considered as events, was 1845 days (Fig. 2) . Because 77.5% of dogs were censored, the CI was not available. The estimated overall MST, where dogs that died from any causes were considered as events, was 1548 days (95% CI: 886-2210). MST calculated only for those seven patients that died of lymphoma was 643 days (range: 399-1845 days) and for the five patients dying of unrelated causes was 789 days (range: 465-4678 days). The 1-, 2-and 4-year overall survival rates for all dogs in this study were 100, 50, and 25%, respectively.
Prognostic factors
There was no statistically significant association between gender, number of presenting clinical signs (one versus multiple), type of clinical signs (systemic versus local), location of the disease (solitary versus multiple/diffuse), involvement of organs other than intestines, immunophenotype (B versus others), grade (high versus others), treatment (chemotherapy alone versus chemotherapy plus a local treatment) (Fig. 3) , chemotherapy treatment (CHOP/doxorubicin-based protocol versus others or CHOP versus others) and either PFS or disease-related MST. The disease-related MST for dogs receiving chemotherapy alone was 1845 days (95% CI: 855-2835) versus a median that could not be reached for dogs receiving chemotherapy plus a local treatment and the difference between these medians was not statistically significant (P = 0.584) (Fig. 3) . When substage was analysed, it was not a statistically significant risk factor for disease-related MST (P = 0.345), but substage b was found to have a significantly positive impact on PFS (P = 0.001), with a PFS that was not reached for dogs categorized as substage b (95% CI: 0-2331.5) versus a PFS of 271 days for dogs without clinical signs at diagnosis. The presence of haematochezia at diagnosis was not a statistically significant risk factor for disease-related MST (P = 0.147) but was found to have a significantly positive impact on PFS (P = 0.02), with a PFS of 1141 days for dogs without haematochezia (95% CI: 0-2331.5) versus a PFS that was not reached for dogs with haematochezia at presentation. Dogs younger than 7 years had longer PFS than dogs older than 7 years (836 days for older dogs, 95% CI: 537-1135 versus a PFS not reached for younger dogs, P = 0.031 and 0.01, respectively) but a similar disease-related MST was present in both groups.
Discussion
The primary goal of the current study was descriptive, as PCRL has not previously been described in a large case series in the veterinary literature and just few sparse cases of colorectal lymphoma have been reported (Table 1) . The current study showed that PCRL occurs primarily in middle-aged dogs with no sex or breed predisposition. Results of this study suggested that PCRL is typically high-grade and B-cell immunophenotype with most dogs presenting as substage b. The majority of dogs (23/31; 74.2%) presented with a solitary mass and 13/31 (43.7%) had evidence of involvement of abdominal extra-GI organs (liver or regional lymph nodes). The disease features of dogs with PCRL described in this study are consistent with cases previously reported. 3 -5,8,10,15 Results of this study suggest that dogs with PCRL treated with chemotherapy, with or without additional local therapy, had a very good prognosis as demonstrated by a high response rate, long PFS and long MST. This is in agreement with previous published results, 3 -5,8,10,15 and in contrast to the reported low response rate (56%) 4 and short survival time (13-77 days) for dogs with diffuse GI tract lymphoma of other locations. 4, 5 The CI could not be calculated for disease-related MST, despite a median follow-up time of almost 2 years, as 14 (45%) of the dogs in this study were still alive at the time of writing. Therefore, it is possible that the PFS and survival time for dogs with PCRL might be even longer than has been estimated in our study. For a more accurate determination of disease-related MST, the population in this study would require follow-up beyond 2 years. The possibility of additional deaths unrelated to lymphoma for dogs currently alive and in complete remission besides the five already recorded, could continue adding censored dogs to the statistical analysis which will make it difficult to reach a defined value for PFS and disease-related MST. We considered that the improved prognosis of dogs with PCRL found in this study, particularly in comparison to previously published outcomes of dogs with AL lymphoma, warranted communication to the veterinary community despite availability only of estimated statistical parameters via the Kaplan-Meier method.
A subsequent goal of our study was to evaluate outcome with different treatment modalities for dogs with PCRL. No statistical difference was found between PFS or survival of dogs receiving chemotherapy only versus chemotherapy plus local treatment with surgery or radiation. Patients that received chemotherapy only had a PFS of 1318 days and a disease-related MST of 1845 days, and the PFS and disease-related MST were not reached for patients that had chemotherapy combined with local treatment, however, this difference in outcome was not statistically significant. This finding shows that chemotherapy alone was effective to treat a localized presentation of lymphoma and surgery or radiation therapy, which carries some morbidity, might delay start of medical anticancer treatment, and increase total cost of therapy, are not necessarily required to achieve a good outcome.
In this study, surgery was performed mainly in cases with presumed solitary large intestine masses primarily to achieve a diagnosis, and we lack information documenting if alternative diagnostic procedures were previously attempted unrewardingly or why surgery was elected by referring vets as a diagnostic tool above other diagnostic modalities. It is possible that the differential diagnosis of PCRL and its implications in the therapeutic approach were not considered because of its rarity in comparison with other types of colorectal neoplasia for which surgery is routinely recommended. The findings in this study support consideration of PCRL as a differential for solitary colorectal masses and when possible the use of low invasive diagnostic techniques such as cytology or incisional biopsy prior to treatment planning. Because of the retrospective nature of the study, treatment groups were not randomized and there is a possibility that surgery had been selected more often for dogs with more advanced diseases and that multimodality treatment would be more beneficial than a single treatment for advanced disease. On the contrary, surgery may also have been elected more often for dogs with isolated disease, and it might have made a difference in the outcome of PCRL patients, as this has been described for solitary lesions of lymphoma in other locations. 15 -17 In this study, there was no difference in PFS or survival time based on the type of chemotherapy protocol used to treat dogs with PCRL. We have to be very cautious in the interpretation of our data considering that, because of the small number of dogs in this study, only two chemotherapy groups could be defined (doxorubicin-based protocol versus others). Still, it is important to consider that these results describe that less intense chemotherapy protocols, often chosen when facing client economic or time constraints or when clients seek therapies with potentially lower prevalence of adverse effects, seem to achieve similar PFS and survival times than with CHOP type protocols. This finding correlates with the previous studies where an overall survival time of approximately 4.5 years was reached in nine dogs with rectal lymphoma receiving either a low dose COP protocol or a truncated (6 weeks) CHOP protocol. 10 Age greater than 7 years was associated with a significantly decreased prognosis when compared with dogs younger than 7 years. Because most dogs had long PFS, it is possible that older patients were more likely to succumb to concurrent or subsequent morbidities than younger dogs. Decreased owner motivation to restart treatment at relapse in older dogs is also a possible reason that these dogs had a shorter disease-related MST when compared with younger dogs, but this would not explain the shorter PFS experienced by dogs older than 7 years.
Canine lymphoma patients with systemic signs or clinical signs associated to their presentation with a systemic impact (substage b) are known to have a worse prognosis. 1,18 -20 Dogs with AL are often substage b at diagnosis mainly because of the clinical signs associated to local disease, and it is possible that they often are less responsive to therapy because of clinical signs being surrogate markers of more advanced disease. 5, 14 GI signs, particularly upper GI signs such as anorexia and vomiting, are often perceived as poor quality of life by owners, leading to an early decision of euthanasia during the course of treatment. In this study, although most dogs presented with clinical signs associated to PCRL, their symptoms did not appear as severe in nature as GI signs of dogs with diffuse small intestinal or gastric lymphoma. We decided to consider haematochezia, tenesmus and diarrhoea as markers of systemic illness because of the possible associated systemic discomfort and pain and potential impact in quality of life. Being this a retrospective study with limited recorded information about severity of clinical signs and impact on the dogs' general status, grading of GI signs at presentation according to the veterinary co-operative oncology group (VCOG) criteria 21 was not possible and precluded a comparison with previous studies about canine AL. Interestingly, in this study, there was no difference in outcome for dogs with systemic versus local signs and substage did not have an impact in survival time. Although PFS of dogs without clinical signs was shorter than for dogs with substage b (271 days versus not reached), these results could have been biased because of the small number of dogs in the substage a group or potential missing data regarding patient's clinical signs. More information is needed to ascertain how best to apply the current canine lymphoma staging system to extranodal forms like PCRL and to identify its value in determining prognosis.
The presence of haematochezia at diagnosis was found to have a positive impact on the PFS compared with other signs. For the 20 dogs presenting with haematochezia, the PFS was not reached, compared with 1141 days for 9 dogs without haematochezia but with other clinical signs. It is not clear why haematochezia would have a positive impact on the prognosis. Perhaps, this was more alarming for owners than diarrhoea and its observation might have led to earlier diagnosis and treatment. On the other hand, we can also assume that other signs reported (diarrhoea, rectal prolapse and tenesmus) might be associated with more advanced disease and decreased outcome, however 13/20 cases with haematochezia also had additional clinical signs. This result could also be secondary to a statistical bias; a larger population would help to determine if the presence or absence of haematochezia truly has an impact on prognosis.
In previous studies on canine AL, the immunophenotype was most commonly of T-cell origin. 5,6,8,22 -24 We report here that colorectal lymphoma is most commonly of B-cell origin, raising a clear distinction from other GI locations. The B-cell phenotype in canine high-grade lymphoma is generally associated with a better response to conventional chemotherapy protocols, compared with the T immunophenotype. 18, 25 In this study, 77% of the dogs were of immunophenotype B, there were only two cases of known non-B immunophenotype with outcomes comparable with the ones with immunophenotype B (survival times 491 and 1273 days) and five cases with unknown immunophenotype (Table 2) . We did not find any impact of immunophenotype on the outcome but the low number of dogs with non-B phenotype included in the study clearly precludes knowing the real impact of this factor in PCRL.
The most common grade for lymphoma found in this study was high (58% of the dogs) and was not a significant prognostic factor in our population. 12 ), reinforcing the fact that anatomic site seems to be a better predictor of outcome than previously published prognostic factors. Information available for staging of dogs included in this study was limited because of its retrospective nature, and staging performed was quite heterogeneous because of the high number of participating institutions. This was unfortunately unavoidable when trying to compile a large case series of PCRL because of its low prevalence. Staging was not complete for all dogs and different imaging modalities were used. In addition, even imaging techniques used routinely for staging in veterinary oncology such as abdominal ultrasound or computed tomography have limitations for detection of lymphoma. Also, aspirates of liver and spleen were not routinely performed despite knowledge that neoplastic infiltration is possible even with a normal imaging appearance. 28 In this study, 12 dogs had evidence of regional lymphadenopathy and 1 hepatic involvement without impact on PFS or survival time. It is very possible that a higher number of dogs had a higher stage of disease than recorded leading to erroneous staging classification of cases (stage migration) 29 and this could explain the lack of statistical difference. On the other hand, given the overall long PFS and survival times for all patients, it could also be thought that possibly under-staged dogs had a good outcome. Based on this study's data, it appears that presence of complete staging would not have provided any further prognostic information for dogs with PCRL. However, as there is no established standard treatment for PCRL, it would be advisable that complete staging would be performed to outweigh potential advantages versus morbidity/cost if considering local therapy prior to chemotherapy or as solely therapy in PCRL.
Human primary AL is classified as confined to the GI tract, with no other evidence of systemic involvement (see Fig. 1 ). They are most often of B-cell origin, 8 which is comparable to our study findings, but opposite to the immunophenotype of canine AL. 6 PCRL is a rare disease in human medicine 30 with controversy about what the standard of care should be for its treatment. 30 Long survivals have been described with 83% of the patients alive and free of disease at 10 years after a combination of surgery and chemotherapy, 31 but shorter prognosis with a 5-year survival rate of 47% has also been reported. 32 In people, the two most frequent histologic subtypes of PCRL are mucosa-associated lymphoid tissue (MALT) lymphoma and diffuse large B-cell lymphoma with both PCRL types carrying very different prognosis. The MALT form, of low grade and B-cell origin, can be cured after surgical resection and/or a short course of chemotherapy. The prognosis is more guarded for the diffuse large B-cell lymphoma which carries a high relapse rate (33-75%). 33 Interestingly, although most cases of canine PRCL in our population were high-grade and B-cell origin, the biologic behaviour appears to differ from the high-grade form of human PRCL.
The limitations of this study are inherent to its retrospective design and include small sample size, variable staging and treatment regimens, and lack of standardized follow-up. The small population because of the rarity of the disease limited the statistical power of our analyses and prognostic factors associated with PFS and disease-related MST may not have been identified because of the variations in staging and treatment protocols. Of the factors analysed, few were found to be prognostic indicators in exploratory univariate analysis. Unfortunately, multivariate analysis could not be carried out as too many dogs were censored mostly because of long survival, loss of follow-up or death from unrelated cause. Evaluation of a larger sample size, prospectively, over a longer period of time including standardized comprehensive staging and standardized therapy would be ideal and may permit determination of additional characteristics and identify risk factors for PCRL. This would be challenging, requiring even further collaboration than the one required for this study (with 18 institutions collaborating in 4 countries) because of the low prevalence of this presentation of canine lymphoma. It needs to be reinforced that larger number of dogs and longer follow-up may still not reach statistical significance if most patients do not demonstrate events linked to their lymphoma (relapse or death) as they would remain censored from the whole population should they remain in remission or die from other causes.
In conclusion, results of this study describe canine PCRL as a rare disease often of high-grade and B-cell immunophenotype that when treated with chemotherapy results in prolonged PFS and survival times regardless of chemotherapy protocol type or addition of local treatment modalities. Results of this study suggest that PCRL has a greatly improved outcome compared with previously published outcomes of dogs with AL. Therefore, attempts to differentiate dogs with PCRL from dogs with diffuse GI lymphoma should be pursued in order to better guide owners regarding treatment and associated prognosis. Veterinarian awareness of this specific presentation of canine lymphoma will likely have an important impact on the treatment decision process for owners of dogs with PCRL.
